Replies to post #1577 on ImmunityBio Inc (IBRX)

[TheFinalCD]

-55%

$IBRX received FDA CRL

Recall position was a catalyst play and not an investment which I clearly outlined in my thread.

Multiple times I tweeted that I closed my full position as stock appreciated a lot from entry point (Below $2) to almost 6+

Risk management is important for…

— Pharmdca (@Pharmdca) May 11, 2023